Prasinezumab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

17 competitors in Parkinson's Disease

#DrugCompanyPhaseTrials

1

Ingrezza

Neurocrine Biosciences

Approved

—2

Nourianz

Kyowa Kirin Co., Ltd.

Phase 3

123

Requip Xl

GGlaxo Dba Glaxosmithkline

Phase 3

74

Comtan

Orion Corporation, Orion Pharma

Phase 2

35

Kisunla

Eli Lilly

Phase 2

—6

Leqembi

Eisai

Phase 2

—7

Nuplazid

AACADIA Pharmaceuticals Inc.

Phase 2

18

Prasinezumab

Roche

Phase 3

39

Ongentys

AAmneal Pharmaceuticals, LLC

Phase 1

310

ND0612

NNeuroDerm Ltd.

Phase 2

4Show 4 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Parkinson's Disease3 trials

Prevent Cognitive Decline in GBA-associated Parkinson's Disease

Not yet recruiting·UUniversity Hospital Tuebingen·Phase 2·NCT07055087·120 enrolled

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease

Recruiting·Roche·Phase 3·NCT07174310·900 enrolled

A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

Active, not recruiting·Roche·Phase 2·NCT04777331·586 enrolled

Details

Drug Info

Related News